Immunosuppressive therapy and kaposi's sarcoma after kidney transplantation

2004 ◽  
Vol 36 (1) ◽  
pp. 168-170 ◽  
Author(s):  
G Moray ◽  
Ö Başaran ◽  
M.C Yağmurdur ◽  
R Emiroğlu ◽  
N Bilgin ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Immunosuppressive Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

IMMUNOSUPPRESSIVE THERAPY AND KAPOSI'S SARCOMA AFTER KIDNEY TRANSPLANTATION

2002 ◽  
Vol 60 (6) ◽  
pp. 558-558 ◽  
Author(s):  
M Haberal ◽  
G Moray ◽  
T Çolak ◽  
MC Yagmurdur
Keyword(s):  
Kidney Transplantation ◽  
Immunosuppressive Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

scholarly journals Long-term therapy of Kaposi’s sarcoma with the use of prospidium chloride and mTOR receptor inhibitors in а patient after kidney transplantation

2020 ◽  
Vol 12 (3) ◽  
pp. 213-219
Author(s):  
E. V. Parabina ◽  
B. I. Yaremin ◽  
M. M. Kaabak
Keyword(s):  
Kidney Transplantation ◽  
Clinical Outcome ◽  
Immunosuppressive Therapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Term Therapy ◽  
Long Term Therapy ◽  
Term Management

A case of a long-term management of a patient with Kaposi’s sarcoma developed as presumably related to a “standard” immunosuppressive therapy after kidney transplantation has been described. Immunosuppressive therapy conversion to mTOR receptor inhibitors and administering chemotherapy with prospidium chloride allowed for a long-term remission of the disease and a satisfactory clinical outcome.

scholarly journals WHAT IS THE ROLE OF HHV 8 IN ETIOPATHOGENESIS OF KAPOSI'S SARCOMA OCCURRED AFTER KIDNEY TRANSPLANTATION?

1998 ◽  
Vol 65 (12) ◽  
pp. S149
Author(s):  
A. T??th ◽  
J. J??ray ◽  
D. G??r??g ◽  
K. Nagy ◽  
B. Szende ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

Treatment of Kaposi's sarcoma after solid organ transplantation.

1997 ◽  
Vol 15 (6) ◽  
pp. 2371-2377 ◽  
Author(s):  
F A Shepherd ◽  
E Maher ◽  
C Cardella ◽  
E Cole ◽  
P Greig ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Organ Transplantation ◽  
Combination Chemotherapy ◽  
Kaposi's Sarcoma ◽  
Solid Organ Transplantation ◽  
Kaposi’S Sarcoma ◽  
Skin Toxicity ◽  
Solid Organ ◽  
Duration Of Response ◽  
Italian Origin

PURPOSE This retrospective review of all patients who developed Kaposi's sarcoma (KS) after solid organ transplantation at a single institution was undertaken to define the clinical presentation of this malignancy in the setting of iatrogenic immunodeficiency, and to determine the most appropriate treatment for patients in this clinical setting. MATERIALS AND METHODS The records of 2,099 patients who underwent heart, lung, liver, or kidney transplantation at The Toronto Hospital between January 1, 1981 and June 30, 1995, were reviewed. Twelve patients were identified who developed biopsy-proven KS in the posttransplantation period. Five patients who had disseminated KS who had not responded to either reduction or withdrawal of immunosuppression or to local radiotherapy were treated with combination chemotherapy consisting of doxorubicin 20 to 30 mg/m2, bleomycin 10 mg/m2, and vincristine 2 mg (ABV) administered intravenously every 3 weeks. RESULTS Eight of 12 patients were male and nine were of Italian origin. KS was limited to a localized area of the skin for only six patients, all after kidney transplantation. Visceral KS was present in three patients. Four of five patients responded to ABV chemotherapy (two complete and two partial remissions). The fifth patient responded to second-line etoposide and cisplatin. The median duration of response was in excess of 13 months (range, 8+ to 45+ months). Toxicity was limited to grade 1 neurotoxicity and grade 1 skin toxicity. CONCLUSION KS is an uncommon but recognized complication of solid organ transplantation. Combination chemotherapy is a safe and effective treatment for patients with disseminated or visceral KS that fails to respond to changes in immunosuppression.

Kaposi's Sarcoma Complicating Immunosuppressive Therapy for Angioimmunoblastic Lymphadenopathy with Dysproteinemia

1982 ◽  
Vol 68 (6) ◽  
pp. 537-542 ◽  
Author(s):  
Mario Cazzola ◽  
Gaetano Bergamaschi ◽  
Alessandro Castello ◽  
Corrado Del Forno ◽  
Laura Dezza ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Immunosuppressive Therapy ◽  
Combination Chemotherapy ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Homosexual Men ◽  
Conservative Approach ◽  
Internal Organs ◽  
Angioimmunoblastic Lymphadenopathy

Cutaneous and visceral dissemination of Kaposi's sarcoma (KS) occurred in a patient with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) who had been treated with combination chemotherapy. Three other cases of KS complicating immunosuppressive therapy of AILD have been reported in the literature, and there is evidence to indicate that AILD displays features which are known to predispose to KS. Like in other subjects with profound immunodeficiency (e.g. in young homosexual men), in our patient KS pursued an unusually aggressive course, with involvement of lymph nodes and internal organs as well as the skin. It is concluded that the risk of developing severe KS is a further reason to avoid aggressive combination chemotherapy in patients with AILD, particularly in those of Jewish or Mediterranean ancestry. Even the use of corticosteroids should be reduced to a minimum to avoid immunosuppression, and a conservative approach to treatment seems advisable.

Kidney transplantation and kaposi’s sarcoma: review of 2050 recipients

2001 ◽  
Vol 33 (5) ◽  
pp. 2818 ◽  
Author(s):  
M Lessan-Pezeshki ◽  
B Einollahi ◽  
M.R Khatami ◽  
M Mahdavi
Keyword(s):  
Kidney Transplantation ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma

Post kidney transplantation Kaposi's sarcoma: the experience of a Mediterranean North African center

2016 ◽  
Vol 30 (4) ◽  
pp. 372-379 ◽  
Author(s):  
Imen Gorsane ◽  
Mohamed Mongi Bacha ◽  
Ezzedine Abderrahim ◽  
Nadia Amri ◽  
Malika Hajri ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
North African
Sign in / Sign up

Export Citation Format

Share Document